內地第五批藥品國採明日開標 集採有58個品種137個品規將被納入
據《經濟參考報》報道,內地第五批國家藥品集採品種的價格申報和供應地區確認將於明日(23日)進行,多家上市藥企趕在開標前夕「踩點」過評,以獲得國採競標「入場券」。
從此前發佈的採購名單看,此次集採共有58個品種137個品規被納入,是品種數量最多的一次。藥品涉及疾病領域包括腫瘤化療藥物、消化製劑、抗生素、呼吸、吸入製劑、造影劑、糖尿病藥物、輔助用藥、眼科相關用藥、抗病毒用藥等。其中29個品種爲注射劑,佔比達半數。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.